Interstitial Brachytherapy for Hepatocellular Carcinoma: Analysis of Prognostic Factors for Overall Survival and Progression-Free Survival and Application of a Risk Stratification Model

Abstract

Introduction Interstitial brachytherapy (iBT) is an effective treatment for hepatocellular carcinoma (HCC). Identification of prognostic factors is pivotal for patient selection and treatment efficacy. This study aimed to assess the impact of low skeletal muscle mass (LSMM) on overall survival (OS) and progression free survival (PFS) of iBT in patients with HCC. Methods For this single-center study we retrospectively identified 77 patients with HCC who underwent iBT between 2011 and 2018. Follow-up visits were recorded until 2020. The psoas muscle area (PMA), psoas muscle index (PMI), psoas muscle density (MD), and the skeletal muscle gauge (SMG) were assessed on the L3 level on pre-treatment cross-sectional CT-scans. Results Median overall survival was 37 months. 42 patients (54.5%) had LSMM. An AFP level of >400ng/ml (HR 5.705, 95%CI 2.228-14.606, p=0.001), BCLC stage (HR 3.230, 95%CI 0.972-10.735, p=0.026), and LSMM (HR 3.365, 95%CI 1.490-7.596, p=0.002) showed a relevant association with OS. Weighted hazard ratios were used to form a predictive risk stratification model with three groups: Patients with low-risk (median OS 62 months), intermediate-risk (median OS 31 months), and high-risk (median OS 9 months). The model showed a good prediction of one-year mortality, with an AUC of 0.71. Higher Muscle density was associated with better PFS (HR 0.920, 95%CI 0.881-0.962, p<0.001). Conclusion In patients undergoing interstitial brachytherapy for hepatocellular carcinoma, low skeletal muscle mass is associated with worse overall survival. A risk stratification model based on LSMM, AFP > 400 ng/ml, and BCLC stage successfully predicted patient mortality. The model may support and enhance patient selection.